BRIEF-Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous UrticariaNov 15 (Reuters) - Sanofi SA SASY.PA:
PRESS RELEASE: DUPIXENT SBLA ACCEPTED FOR FDA REVIEW FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA
FDA DECISION ON DUPIXENT EXPECTED BY APRIL 18, 2025
SAFETY RESULTS IN ALL LIBERTY-CUPID PHASE 3 STUDIES WERE GENERALLY CONSISTENT WITH KNOWN SAFETY PROFILE
RESUBMISSION INCLUDES NEW PIVOTAL DATA WHICH CONFIRM DUPIXENT SIGNIFICANTLY REDUCED ITCH AND HIVE ACTIVITY
Source text: ID:nGNX1633wG
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments